RxDoctor Payments Data

Ragoor Reddy, MD

Cardiovascular Disease · Greensburg, PANPI 1336140326

Payments from drug & device makers

$417in general payments, 2019–2025

Across 12 payments — averaging $34.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$121
  • Heartflow, Inc.$116
  • Abbott$68
  • Irhythm Technologies, Inc.$54
  • E.r. Squibb & Sons, L.L.C.$37
  • Pfizer$22

What the payments were for

  • Food & beverage$417100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$417 in reported general payments places this provider in the 20th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$152,532
Medicare patients
459
Services billed
1,694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban475$397,371
EntrestoSacubitril/Valsartan172$155,843
XareltoRivaroxaban154$125,826
Repatha SureclickEvolocumab119$80,168
MultaqDronedarone Hcl76$66,886
BrilintaTicagrelor99$60,803
FarxigaDapagliflozin Propanediol45$30,800
JardianceEmpagliflozin23$15,345
Repatha SyringeEvolocumab28$14,677
Metoprolol Succinate864$12,202
Potassium Chloride421$7,113
Nitroglycerin PatchNitroglycerin88$4,789
Dofetilide13$3,976
Rosuvastatin Calcium370$3,561
Ezetimibe156$3,421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$22$397,371475 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Greensburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →